Bioreactors Market - Global Industry Insights,
Trends, Outlook, and Opportunity Analysis, 2018-
2026
Bioreactor is an engineered or manufactured vessel that is used in the production of wide range
of biological products. Industrial bioreactor is a vessel in which biochemical process is carried
out using microbes and animal cells or biologically active compounds that are derived from
living cells. Bioreactors are cylindrical in shape with capacity of liters to cubic meters and is
the most important component involved in bioprocessing. Fermentation processes such as wine,
and beer production are carried out in bioreactors. Bioreactors for large scale production of
therapeutic products are made of stainless steel. In biopharmaceutical companies, small glass
bioreactors are used for research and development purpose and for scale up activities. Another
type of bioreactors are disposable bioreactors, which are meant for single use and hence are
called as single-use bioreactors. It is generally used for extensive research and manufacturing.
Bioreactors can operate in batch, fed batch, and continuous stirred tank processes. Bioreactors
are used to produce therapeutics, which include monoclonal antibodies, vaccines, stem cells,
and gene modified cells.
Ask For Discount Before Purchasing This Business Report @
https://www.coherentmarketinsights.com/insight/request-discount/1593
Market Drivers
The efficiency of single-use bioreactors has increased across pharmaceutical industries in terms
of production, quality control, and procurement. Single-use bioreactors offer advantages such as
consistency in production, increase in speed of manufacturing, reduced operational cost, and
reduction in manufacturing time of finished dosage form, which foster growth of bioreactors
market. In 2016, as per the National Centre for Biotechnology Information (NCBI), operational
cost per gram of monoclonal antibody production (mAb) for single-use bioreactor is around 22%
lower than conventional system, mainly due to less labor, utilities, maintenance, and waste. For
commercial scale of monoclonal antibody production (mAb), conventional fed-batch bioreactors
usually require 10000L – 25000L stainless steel tank to culture cells and produce yield of 2-6 g/
L. However, single-use bioreactors employ continuous cell culture supply in 500L - 2000L tank